SUPN: Supernus Pharmaceuticals, Inc.
2018-12-20 07:00:00
Supernus Announces Positive Results from Phase III Study For SPN-812 in Adolescents with ADHD
2018-12-20 07:00:00
Supernus Announces Positive Results from Phase III Study For SPN-812 in Adolescents with ADHD
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.